Terpos, E., Gavriatopoulou, M., Ntanasis-Stathopoulos, I., Kanellias, N., Solia, E., Malandrakis, P., Spiliopoulou, V., Theodorakakou, F., Katsadouros, I., Migkou, M., Papaiakovou, E. E., Fotiou, D., Vassalou, H., Kastritis, E., Dimopoulos, M. (2025). Hematologist based management of ocular adverse events using the VRA tool in newly-diagnosed myeloma patients, ineligible for ASCT who received belantamab mafodotin plus lenalidomide/dexamethasone: Updated results from the randomized part 2 of bela-rd Study. Blood. https://doi.org/10.1182/blood-2025-4038